
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is a biopharmaceutical company with a strong focus on discovering and developing small-molecule drugs for various diseases. The company has a robust pipeline, including a market-leading drug, Jakafi, which treats rare blood cancers and has a partnership with Novartis. Incyte also has several other marketed drugs, with a recent FDA approval for its first dermatology product, Opzelura, and upcoming potential approvals for other drugs in its pipeline. With positive financial results and a promising pipeline, Incyte has the potential for significant growth in the future, making it a stock to watch for investors.
Bears say
Incyte is expected to face challenges with its leading drug Jakafi due to competition and potential concerns about its black box warning and cardiometabolic comorbidities in certain patient populations. Despite other promising drugs in its portfolio, such as Olumiant and Monjuvi, the success of its dermatology products, particularly Opzelura for atopic dermatitis and vitiligo, will determine the company's future growth. However, with high payer friction and monitoring requirements, the success of povorcitinib as a bridge between biologics and an alternative for injection-averse patients will be crucial for Incyte's financial performance.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares